These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20217906)

  • 21. Pulsus paradoxus in pulmonary embolism: reversal with thrombolytic therapy.
    Silverman HJ; Haponik EF
    Crit Care Med; 1986 Feb; 14(2):165-6. PubMed ID: 3943323
    [No Abstract]   [Full Text] [Related]  

  • 22. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study.
    Fitzpatrick AL; Kronmal RA; Gardner JP; Psaty BM; Jenny NS; Tracy RP; Walston J; Kimura M; Aviv A
    Am J Epidemiol; 2007 Jan; 165(1):14-21. PubMed ID: 17043079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible mechanisms for the regulation of telomere length.
    Kowald A
    J Mol Biol; 1997 Nov; 273(4):814-25. PubMed ID: 9367774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress.
    Matthews C; Gorenne I; Scott S; Figg N; Kirkpatrick P; Ritchie A; Goddard M; Bennett M
    Circ Res; 2006 Jul; 99(2):156-64. PubMed ID: 16794190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Administration of maximal or median doses of drugs in cardiovascular diseases?].
    Spácil J
    Vnitr Lek; 2003 Apr; 49(4):322-5; discussion 326-7. PubMed ID: 12793058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chronobiologic aspects of therapy for cardiovascular diseases].
    Stepień M; Foks-Fratczak A
    Postepy Hig Med Dosw; 1999; 53(3):483-96. PubMed ID: 10424135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathophysiology of cardiovascular disease and renal failure.
    Dikow R; Zeier M; Ritz E
    Cardiol Clin; 2005 Aug; 23(3):311-7. PubMed ID: 16084280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Endothelium--a new target for a therapeutic action of angiotensin-converting enzyme inhibitors].
    Karpov IuA
    Ter Arkh; 2004; 76(6):94-6. PubMed ID: 15332589
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapeutical perspectives for apoptosis modulation in cardiovascular disease.
    Ginghină C; Crăciunescu I; Iorga V
    Rom J Intern Med; 2006; 44(3):213-22. PubMed ID: 18386601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroid hormones and the cardiovascular system: pathophysiology and interventions.
    Cini G; Carpi A; Mechanick J; Cini L; Camici M; Galetta F; Giardino R; Russo MA; Iervasi G
    Biomed Pharmacother; 2009 Dec; 63(10):742-53. PubMed ID: 19917524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Electrocardiographic studies in patients with infectious hepatitis, cardio-vascular diseases and symptoms of heart and coronary insufficiency during treatment with corticosteroids (prednisolone)].
    Argov IuM
    Ter Arkh; 1968 Jul; 40(7):25-9. PubMed ID: 5739329
    [No Abstract]   [Full Text] [Related]  

  • 32. [The prevention and drug correction of cardiovascular changes in prostatic cancer patients].
    Gembitskiĭ EV; Begunov AV
    Voen Med Zh; 1994 Feb; (2):35-7. PubMed ID: 7513112
    [No Abstract]   [Full Text] [Related]  

  • 33. Angiotensin II AT2 subtype receptors: an emerging target for cardiovascular therapy.
    Volpe M; De Paolis P
    Ital Heart J; 2000 Feb; 1(2):96-103. PubMed ID: 10730608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet-active drugs in the secondary prevention of cardiovascular events: an overview.
    Weiss HJ
    Circulation; 1980 Dec; 62(6 Pt 2):V41-3. PubMed ID: 7002351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological ageing and cardiovascular disease.
    Samani NJ; van der Harst P
    Heart; 2008 May; 94(5):537-9. PubMed ID: 18411343
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of sympathetic activation in cardiovascular disease.
    Cohen JD; Egan BM
    Postgrad Med; 2003 Dec; 114(6 Suppl Role):4-10. PubMed ID: 19667664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vasodilators. 2-Treatment of arterial hypertension, cardiac insufficiency and peripheral vascular diseases].
    Langlois S; Ogilvie RI
    Union Med Can; 1981 Oct; 110(10):850-6. PubMed ID: 7303307
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic implications of the gender-specific aspects of cardiovascular disease.
    Regitz-Zagrosek V
    Nat Rev Drug Discov; 2006 May; 5(5):425-38. PubMed ID: 16672926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Complications associated with sudden withdrawal of various drugs used in the treatment of cardiovascular diseases].
    Halawa B
    Wiad Lek; 1981 Mar; 34(6):491-5. PubMed ID: 6791387
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cardiovascular effects of hyperthyroidism and their treatment].
    Tielens E; Visser TJ; Hennemann G; Berghout A
    Ned Tijdschr Geneeskd; 2002 May; 146(19):890-3. PubMed ID: 12043444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.